medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2024, Number 04

<< Back Next >>

Ginecol Obstet Mex 2024; 92 (04)

Patent blue for identification of sentinel nodes in breast cancer

Urías CJC, Palacios RA, Villegas PR

Language: Spanish
References: 22
Page: 145-152
PDF size: 209.12 Kb.


ABSTRACT

Objective: To describe the sociodemographic, clinical and pathological characteristics and results of the patent blue sentinel lymph node technique in early breast cancer surgery. And to report the experience in identifying the sentinel lymph node in early breast cancer using the 2.5% patent blue technique.
Materials and Methods: Retrospective and analytical study consisting of the evaluation of the clinical records of patients diagnosed with early breast cancer, without clinical or radiological suspicion of axillary involvement, seen between June 2022 and June 2023 at the Oncological Gynaecology Service of the UMAE Hospital de Ginecoobstetricia, Centro Médico Nacional de Occidente of the IMSS. The dye injection site was subdermal periareolar, and the identified lumps were examined in the transoperative period. The percentage of identification, false negative rates and negative predictive value of the method were analysed.
Results: Ninety-five sentinel node biopsies were analysed. Axillary lymphadenectomy was performed only in patients with sentinel lymph node metastasis confirmed at surgery and in those in whom no stained nodes were identified due to non-migration of the dye. The mean age of the patients was 57.1 years (range 25 to 78 years). The tumour size was less than 3 cm. Sixty-four patients (67%) underwent mastectomy, compared with 31 who underwent breast-conserving surgery (33%). Fifty-seven of the 95 patients were staged as AI; the most common molecular subtype was compatible with luminal A in 49%.
Conclusions: Sentinel lymph node biopsy with patent blue is a rapid, simple, accurate and inexpensive technique for identifying axillary disease in early breast cancer. The results reported here represent an initial evaluation of the technique in our service.


REFERENCES

  1. Noguchi M, Inokuchi M, Noguchi M, Morioka E, Ohno Y,Kurita T. Axillary surgery for breast cancer: past, present,and future. Breast Cancer 2021; 28 (1): 9-15. https: //doi.org/10.1007/s12282-020-01120-0

  2. James TA, Palis B, McCabe R, et al. Evaluating the role ofsentinel lymph node biopsy in patients with DCIS treatedwith breast conserving surgery. Am J Surg 2020; 220 (3):654-659. https://doi.org/10.1016/j.amjsurg.2020.01.014

  3. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinellymph node biopsy in early‐stage breast carcinoma. Cancer2006; 106 (1): 4-16. https://doi.org/10.1002/cncr.21568

  4. Veronesi P, Corso G. Standard and controversies in sentinelnode in breast cancer patients. The Breast 2019; 48: S53-S56. https://doi.org/10.1016/S0960-9776 (19): 31124-5

  5. Yuan Q, Wu G, Xiao S-Y, et al. Identification and Preservationof Arm Lymphatic System in Axillary Dissection for BreastCancer to Reduce Arm Lymphedema Events: A RandomizedClinical Trial. Ann Surg Oncol 2019; 26 (11): 3446-54.https://doi.org/10.1245/s10434-019-07569-4

  6. Giuliano AE. Axillary Dissection vs No Axillary Dissectionin Women With Invasive Breast Cancer and SentinelNode Metastasis. JAMA 2011; 305 (6): 569. https://doi.org/10.1001/jama.2011.90

  7. Cserni G, Maguire A, Bianchi S, Ryska A, Kovács A. Sentinellymph node assessment in breast cancer -an update oncurrent recommendations. Virchows Arch 2022; 480 (1):95-107. https://doi.org/10.1007/s00428-021-03128-z

  8. Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. LymphNode Imaging in Patients with Primary Breast Cancer: ConcurrentDiagnostic Tools. Oncologist 2020; 25 (2): e231-e242.https://doi.org/10.1634/theoncologist.2019-0427

  9. Vidya R, Iqbal FM, Bickley B. Pre-operative axillary staging:should core biopsy be preferred to fine needle aspirationcytology? Ecancermedicalscience 2017; 11: 1-6. https://doi.org/10.3332/ecancer.2017.724

  10. Nayak A, Bleiweiss IJ. Iatrogenically false positive sentinellymph nodes in breast cancer: Methods of recognitionand evaluation. Semin Diagn Pathol 2018; 35 (4): 228-35.https://doi.org/10.1053/j.semdp.2017.09.001

  11. Cotarelo CL, Zschöck-Manus A, Schmidt M, et al. Improveddetection of sentinel lymph node metastases allowsreliable intraoperative identification of patients withextended axillary lymph node involvement in early breastcancer. Clin Exp Metastasis 2021; 38 (1): 61-72. https://doi.org/10.1007/s10585-020-10065-9

  12. Pétursson HI, Kovács A, Mattsson J, Olofsson Bagge R.Evaluation of intraoperative touch imprint cytology on axillarysentinel lymph nodes in invasive breast carcinomas, aretrospective study of 1227 patients comparing sensitivityin the different tumor subtypes. Coleman WB, ed. PLoSOne 2018; 13 (4): e0195560. https://doi.org/10.1371/journal.pone.0195560

  13. Jahan S, Al-saigul AM, Abdelgadir MH. NCCN GuidelinesVersion 4.2023 Breast Cancer. J R Soc Med 2016; 70 (8):515-17.

  14. Poodt IGM, Vugts G, Schipper R-J, Nieuwenhuijzen GAP.Repeat Sentinel Lymph Node Biopsy for Ipsilateral BreastTumor Recurrence: A Systematic Review of the Results andImpact on Prognosis. Ann Surg Oncol 2018; 25 (5): 1329-39.https://doi.org/10.1245/s10434-018-6358-0

  15. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operativearm morbidity and quality of life. Results of the ALMANACrandomised trial comparing sentinel node biopsy withstandard axillary treatment in the management of patientswith early breast cancer. Breast Cancer Res Treat 2006; 95(3): 279-93. https://doi.org/10.1007/s10549-005-9025-7

  16. Hashmi AA, Naz S, Ahmed O, et al. Diagnostic Accuracy ofIntraoperative Touch Imprint Cytology for the Diagnosis ofAxillary Sentinel Lymph Node Metastasis of Breast Cancer:Comparison With Intraoperative Frozen Section Evaluation.Cureus 2021; 13 (1): 1-7. https://doi.org/10.7759/cureus.12960

  17. Mamtani A, Barrio A V., Goldman DA, Wen HY, Vincent A, MorrowM. Extranodal Tumor Deposits in the Axillary Fat Indicatethe Need for Axillary Dissection Among T1-T2cN0 Patientswith Positive Sentinel Nodes. Ann Surg Oncol 2020; 27 (10):3585-92. https://doi.org/10.1245/s10434-020-08632-1

  18. Kedrzycki MS, Leiloglou M, Ashrafian H, et al. Meta-analysisComparing Fluorescence Imaging with Radioisotope andBlue Dye-Guided Sentinel Node Identification for BreastCancer Surgery. Ann Surg Oncol 2021; 28 (7): 3738-48.https://doi.org/10.1245/s10434-020-09288-7

  19. Cody HS, Van Zee KJ. Point: Sentinel lymph node biopsy isindicated for patients with DCIS. JNCCN J Natl Compr CancerNetw 2003; 1 (2): 199-206. https://doi.org/10.6004/jnccn.2003.0018

  20. Abe M, Yamada T, Nakano A. Prospective Comparison ofIntraoperative Touch Imprint Cytology and Frozen SectionHistology on Axillary Sentinel Lymph Nodes in Early BreastCancer Patients. Acta Cytol 2020; 64 (5): 492-497. https://doi.org/10.1159/000508016

  21. Giuliano AE, Ballman K, McCall L, et al. Locoregional RecurrenceAfter Sentinel Lymph Node Dissection With orWithout Axillary Dissection in Patients With Sentinel LymphNode Metastases. Ann Surg 2016; 264 (3): 413-420. https://doi.org/10.1097/SLA.0000000000001863

  22. Howard-McNatt M, Geisinger KR, Stewart JH, Shen P,Levine EA. Is intraoperative imprint cytology evaluationstill feasible for the evaluation of sentinel lymphnodes for lobular carcinoma of the breast? Ann SurgOncol 2012; 19 (3): 929-934. https://doi.org/10.1245/s10434-011-2038-z




2020     |     www.medigraphic.com